Clinical Trial Update: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

View source ↗

Summary

A retrospective-prospective Italian study evaluating real-world use and outcomes of zanubrutinib (Brukinsa) in Waldenström's macroglobulinemia under compassiona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Waldenström's Macroglobulinemia (WM) | Status: ACTIVE_NOT_RECRUITING